Annovis Bio's Buntanetap Advances in Alzheimer's and Parkinson's Trials
March 31, 2026 — Annovis Bio announces publication in The Scientist detailing buntanetap development for Alzheimer's and Parkinson's disease, with Phase 3 trials showing strong enrollment progress toward potential breakthrough treatment.